EMA Committee Urges Warning About Hep B Reactivation In Patients Taking DAAs
Executive Summary
The European Medicines Agency’s pharmacovigilance committee wants manufacturers of the direct-acting antivirals for hepatitis C to include a warning about the possibility of hepatitis B reactivation in patients who carry both viruses.